North America Low Molecular Weight Heparin Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Product Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin, and Others), Packaging (Multi-Vials and Prefilled Syringes), Application [Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism, and Others], and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others)


No. of Pages: 129    |    Report Code: TIPRE00027114    |    Category: Life Sciences

North America Low Molecular Weight Heparin Market
Buy Now

The low molecular weight heparin market in North America is expected to grow from US$ 1,232.86 million in 2021 to US$ 1,963.46 million by 2028; it is estimated to grow at a CAGR of 6.9% from 2021 to 2028.

Anticoagulants prevent clotting of blood and the growth of existing blood clots in blood vessels. In recent years, the development of methods for the prevention, and pharmacological and surgical treatment of thrombosis have improved considerably. The LMWHs are being used in the treatment of antithrombotic diseases for the past two decades. Owing to the structural complexity of anticoagulants and the presence of impurities, their structural characterization requires advanced analytical techniques. The LMWH exhibits anticoagulant properties such as anti-tumor, anti-inflammatory, and anti-proliferative effects, which are useful in the treatment of pathologies such as nephrotic syndrome and Alzheimer's disease. The patents of LMWH's have now expired. However, the market potential for LMWH is growing due to the increasing use in several emerging countries owing to its uses, such as thromboprophylaxis, venous thromboembolism (VTE), and anticoagulation treatment during pregnancy. As a result, pharmaceutical companies in many countries are focused on producing generic LMWHs. Enoxaparin is the world's best-selling LMWH. Pharmaceutical companies are also conducting various research and development activities to manufacture enoxaparin biosimilar. This further leads to intense competition in the LMWH market. Pharmaceutical companies either produced biosimilars or renamed the generic versions of the branded LMWH. In particular, copies of enoxaparin are available mainly in North America, which is further anticipated to drive the market in North America.

 

North America is highly affected due to the COVID-19 pandemic. This led to increased demand for diagnosing and therapeutic devices in hospitals. The FDA has increased its efforts to provide healthcare to people and has imposed several guidelines for hospitals and medical device companies. Various companies also enhanced their research and development activities for diagnostics tests and therapeutic devices. Despite facing the ill effects of SARS and H1N1 outbreaks in the last few years, the severity of the COVID-19 pandemic made the situation more complicated for the healthcare sectors due to its mode of transmission. The ongoing pandemic is straining public health systems globally, interrupting and delaying critical healthcare procedures. As per the IRI data, demand for various dietary supplements grew after the onset of the COVID-19 pandemic in the US at unprecedented rates. The total supplement sales increased by 6% during the first week of March 2020.

 

North America Low Molecular Weight Heparin Market Revenue and Forecast to 2028 (US$ Million)

North America Low Molecular Weight Heparin Market Revenue and Forecast to 2028 (US$ Million)
Get more information on this report

North America Low Molecular Weight Heparin Strategic Insights

Strategic insights for the North America Low Molecular Weight Heparin provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/north-america-low-molecular-weight-heparin-market-strategic-framework.webp
Get more information on this report

North America Low Molecular Weight Heparin Report Scope

Report Attribute Details
Market size in 2021 US$ 1,232.86 Million
Market Size by 2028 US$ 1,963.46 Million
Global CAGR (2021 - 2028) 6.9%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Product Type
  • Enoxaparin
  • Dalteparin
  • Tinzaparin
  • Fraxiparine
  • Nadroparin
By Packaging
  • Multi-Vials and Prefilled Syringes
By Application
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome
  • Pulmonary Embolism
By End User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Market leaders and key company profiles
  • Abbott
  • Aspen Holdings
  • B. Braun Medical Inc.
  • Dr. Reddy's Laboratories
  • LEO Pharma A/S
  • Novartis
  • Pfizer Inc.
  • Sanofi
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Get more information on this report

    North America Low Molecular Weight Heparin Regional Insights

    The geographic scope of the North America Low Molecular Weight Heparin refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/north-america-low-molecular-weight-heparin-market-geography.webp
    Get more information on this report

    North America Low Molecular Weight Heparin Market Segmentation 

     

    North America Low Molecular Weight Heparin Market – By Product Type

    • Enoxaparin
    • Dalteparin
    • Tinzaparin
    • Fraxiparine
    • Nadroparin
    • Others

    North America Low Molecular Weight Heparin Market – By

    Packaging

    • Multi-Vials
    • Prefilled Syringes

    North America Low Molecular Weight Heparin Market – By

    Application

    • Deep Vein Thrombosis
    • Acute Coronary Syndrome (ACS)
    • Pulmonary Embolism
    • Others

    North America Low Molecular Weight Heparin Market – By

    End User

    • Hospitals
    • Clinics
    • Ambulatory Surgical Centers
    • Others

    North America Low Molecular Weight Heparin Market– By Country

    • US
    • Canada
    • Mexico

    North America Low Molecular Weight Heparin Market-Companies Mentioned

    • Abbott
    • Aspen Holdings
    • B. Braun Medical Inc.
    • Dr. Reddy's Laboratories
    • LEO Pharma A/S
    • Novartis
    • Pfizer Inc.
    • Sanofi
    • TEVA PHARMACEUTICAL INDUSTRIES LTD

    The List of Companies - North America Low Molecular Weight Heparin Market

    1. Abbott
    2. Aspen Holdings
    3. B. Braun Medical Inc.
    4. Dr. Reddy's Laboratories
    5. LEO Pharma A/S
    6. Novartis
    7. Pfizer Inc.
    8. Sanofi
    9. TEVA PHARMACEUTICAL INDUSTRIES LTD
    Frequently Asked Questions
    How big is the North America Low Molecular Weight Heparin Market?

    The North America Low Molecular Weight Heparin Market is valued at US$ 1,232.86 Million in 2021, it is projected to reach US$ 1,963.46 Million by 2028.

    What is the CAGR for North America Low Molecular Weight Heparin Market by (2021 - 2028)?

    As per our report North America Low Molecular Weight Heparin Market, the market size is valued at US$ 1,232.86 Million in 2021, projecting it to reach US$ 1,963.46 Million by 2028. This translates to a CAGR of approximately 6.9% during the forecast period.

    What segments are covered in this report?

    The North America Low Molecular Weight Heparin Market report typically cover these key segments-

    • Product Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin)
    • Packaging (Multi-Vials and Prefilled Syringes)
    • Application (Deep Vein Thrombosis, Acute Coronary Syndrome, Pulmonary Embolism)
    • End User (Hospitals, Clinics, Ambulatory Surgical Centers)

    What is the historic period, base year, and forecast period taken for North America Low Molecular Weight Heparin Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Low Molecular Weight Heparin Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in North America Low Molecular Weight Heparin Market?

    The North America Low Molecular Weight Heparin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Abbott
  • Aspen Holdings
  • B. Braun Medical Inc.
  • Dr. Reddy's Laboratories
  • LEO Pharma A/S
  • Novartis
  • Pfizer Inc.
  • Sanofi
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Who should buy this report?

    The North America Low Molecular Weight Heparin Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Low Molecular Weight Heparin Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now